In this issue of the Journal, Roberto Pontremoli and his coauthors propose a practical
approach for the prescription of SGLT2 inhibitors (SGLT2i) in patients with heart failure [1] …

The treatment and management of heart failure (HF) are constantly evolving. The latest
guidelines recommend the use of SGLT2 inhibitors (SGLT2i) as an integral part to treating …

Introduction Sodium-glucose co-transporter (SGLT2) inhibition has been shown to reduce
the risk of cardiovascular death or hospitalisation in patients with heart failure with reduced …

• DELIVER (Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection
Fraction) 1 is an industry-funded Phase 3, double-blind, event-driven, randomized …

It is highly improbable and incredibly fortuitous for a therapy to work across an entire
syndrome. As luck would have it, that syndrome is heart failure—perhaps the most common …

Since the publication of the EMPA-REG-Outcome trial, there has been huge interest in the
potential benefit of sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients with heart …

The European Society of Cardiology's (ESC) guidelines on heart failure were revised for the
first time in five years and presented at an online ESC conference held from 27 August to 30 …

The constantly expanding population of heart failure (HF) patients over the last few decades
in cardiology practice has successfully compelled cardiovascular (CV) research to evolve …

The sodium glucose cotransporter inhibitors (SGLTis) have proven effective in preventing
the development of heart failure (HF) in patients with Type 2 diabetes (T2DM) as well as in …

Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors dapagliflozin or
empagliflozin are recommended, in addition to optimal medical therapy (OMT), for patients …